What's Happening?
VectorBuilder, a leader in gene delivery technologies, is set to participate in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting from May 11 to 15 in Boston, Massachusetts. The company
will present on the importance of therapeutic vector design in gene and cell therapies, which are nearing clinical and commercial scales. Dr. Bruce Lahn, Chief Scientist at VectorBuilder, will deliver a session titled 'From Research to Clinic: A Practical Guide to Optimizing Therapeutic Vector Design' on May 13. The presentation will address how early vector design decisions impact manufacturability, consistency, and downstream outcomes. Additionally, VectorBuilder scientists will present new research on AAV vector engineering, focusing on improving vector stability, payload efficiency, and scalability.
Why It's Important?
The participation of VectorBuilder in the ASGCT Annual Meeting underscores the growing significance of vector design in the gene therapy industry. As gene and cell therapies advance towards clinical and commercial applications, the need for efficient and reliable vector design becomes critical. This development has implications for the biotech and pharmaceutical sectors, as it could lead to more effective therapies and streamlined production processes. The focus on vector design aligns with the industry's shift towards integrating research with clinical and manufacturing requirements, potentially reducing variability and enhancing therapeutic outcomes.
What's Next?
VectorBuilder's presentations at the ASGCT Annual Meeting are expected to foster discussions among researchers, clinicians, and industry leaders about the future of gene therapy. The insights shared could influence future research directions and collaborations, as well as inform regulatory strategies. As the field progresses, stakeholders may focus on refining vector design processes to meet evolving clinical and commercial demands, potentially accelerating the development of new therapies.
